Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange

Pentixapharm Holding AG (“Pentixapharm”) made its debut today in the Prime Standard of the Frankfurt Stock Exchange under the ticker symbol PTP and the international securities identification number (ISIN) DE000A40AEG0. The initial trading price was EUR 5.10, resulting in a market capitalization of EUR 126.5 million at the start of trading.

 

  • Spin-off from Eckert & Ziegler SE completed
  • First trading price at EUR 5.10
  • Market capitalization of EUR 126.5 million
  • Book-entry delivery of shares scheduled for next week
  • Funding secured for upcoming milestones

 

 

Pentixapharm Holding AG (“Pentixapharm”) made its debut today in the Prime Standard of the Frankfurt Stock Exchange under the ticker symbol PTP and the international securities identification number (ISIN) DE000A40AEG0. The initial trading price was EUR 5.10, resulting in a market capitalization of EUR 126.5 million at the start of trading. The biopharmaceutical company focuses on developing innovative first-in-class radiopharmaceuticals for the diagnosis and therapy (theranostics) of blood cancers and other widespread indications that are currently untreated by radiopharmaceuticals.

The spin-off from Eckert & Ziegler SE was completed yesterday following registration in the commercial register. As an independent listed company, Pentixapharm is financially well-positioned with approximately EUR 19.9 million in gross proceeds from the IPO placement, along with additional funding from the issuance of a convertible bond worth EUR 18.5 million to Eckert & Ziegler SE. This solid financial base allows Pentixapharm to continue advancing its growth strategy, with a focus on the clinical development and approval of its lead candidates Ga68-PentixaFor and Y90-PentixaTher.

Dr. Hakim Bouterfa, CEO of Pentixapharm Holding AG, stated: “We are thrilled by the strong interest shown by investors and the media in our IPO. The listing provides us with the flexibility to finance our growth in stages and to continually attract new investors who want to share in Pentixapharm’s long-term success. Through partnerships with leading companies in the biopharma industry, we aim to expand both our technological and commercial reach.”

Today’s listing included both the existing shares and the spin-off shares. The offer shares will be traded starting October 10, 2024, following the registration of the capital increase in the commercial register and approval by Deutsche Börse AG. The book-entry delivery is scheduled for October 7, 2024, for the spin-off shares and October 10, 2024, for the offer shares.

BankM AG acted as Sole Global Coordinator and Sole Bookrunner for the transaction. MC Services AG acted as the selling agent (tied agent of CapSolutions GmbH) and also served as press and investor relations advisor. Legal advice was provided by HEUKING.

About Pentixapharm Holding AG

Pentixapharm Holding AG was founded in 2024 to incorporate all shares held by Eckert & Ziegler SE in Pentixapharm AG, based in Würzburg, following the spin-off resolved by the Annual General Meetings of Eckert & Ziegler SE and Pentixapharm Holding AG on June 26, 2024. Pentixapharm Holding AG is listed in the Prime Standard of the Frankfurt Stock Exchange.

Pentixapharm AG is a clinical-stage radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Pentixapharm’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Clinical studies for both compounds have already commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. Additionally, PentixaFor is being developed as a diagnostic tool for primary aldosteronism (PA), a major cause of hypertension. Pentixapharm is currently preparing a US-centric Phase III registration study with PentixaFor in PA that will start in 2025.

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
phillip.eckert@noSpampentixapharm.com
Tel. +49 30 94 10 84 227
www.pentixapharm.com

Media Contact:
MC Services AG
Anne Hennecke
Tel. +49 211 529252 22
anne.hennecke@noSpammc-services.eu

 

Back